Drug Type Small molecule drug |
Synonyms Envlomet SR Tab., Envlomet Sustained Release, Envolomet + [4] |
Target |
Mechanism PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (14 Jun 2023), |
Regulation- |
Molecular FormulaC24H27ClO6 |
InChIKeyKORCWPOBTZTAFI-YVTYUBGGSA-N |
CAS Registry1415472-28-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | KR | 14 Jun 2023 |